Just two injections a year of an antiviral drug entirely prevented HIV infection among more than 2,000 women and girls enrolled in a clinical trial 1. The drug, lenacapavir, is made by Gilead Sciences ...

HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...

Antiviral drugs almost completely reduce the risk of mothers passing on HIV infection to their children, even in a low-income country with a high HIV incidence such as Tanzania, according to a new ...

Gilead said Thursday that twice-a-year injections of a new antiviral drug, called lenacapavir, completely protected cisgender women from contracting HIV in a large Phase 3 trial. In the study, none of ...

Shares of Gilead Sciences (NASDAQ:GILD) reached a session high on Wednesday after the U.S. Food and Drug Administration (FDA) approved its antiviral therapy lenacapavir as a twice-yearly injectable ...

Coronaviruses are a global public health risk, with three highly infectious species, including SARS-CoV-2, emerging in the last 20 years. New research by the University of Bristol has shown how an HIV ...